Axonics® announces ce mark approval for implantable sacral neurostimulator that significantly extends recharge interval

Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced european ce mark approval of its second generation axonics r-snm® implantable neurostimulator (ins) and wireless patient remote control with smartmri™ technology. axonics previously received u.s. food & drug administration approval for this ins and remote control during 202
AXNX Ratings Summary
AXNX Quant Ranking